Drugs / TR1801-ADC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03859752 | Aug 2019 → Jul 2023 | cancer of unknown primary site | Open Innovation Partners, Inc. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TR1801-ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03859752 ↗ |
| Modality | Monoclonal antibody | “Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin” NCT03859752 ↗ |